Abstract
T HE EVOLUTION of bone marrow transplantation (BMT) from purely experimental therapy for patients in leukemic relapse to the indicated treatment for certain malignancies and congenital disorders has been a result of multiple factors.‘.2 Major strides in the field of immunobiology have provided the basis for a more rational clinical approach to bone marrow transplant candidates.” In particular, further understanding of the major histocompatibility complex (MHC), which encompasses the genes for human leukocyte antigens (HLA), has improved our ability to select an appropriate marrow donor.3 As increasing numbers of institutions are offering bone marrow transplants as a treatment option, various issues pertinent to the role of the donor are arising. These issues, which may affect the recipient’s clinical course as well as the donor’s well being, are discussed.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
